Nicotinamide adenine dinucleotide (NAD+) sits at the crossroads of nearly every major metabolic process in your body. Over the past decade, it has become one of the most intensely studied molecules in aging research — and for good reason. NAD+ levels decline measurably with age, and that decline intersects with multiple hallmarks of aging that scientists have identified as drivers of biological deterioration.
But what does the research actually show? Where does robust human data exist, and where are we still extrapolating from animal models? This page breaks down the mechanistic science behind NAD+ and longevity, examines the current state of clinical evidence, and explains how clinician-supervised NAD+ therapy fits into the broader landscape of proactive health optimization.
---
What Is NAD+ and Why Does It Matter for Aging?
NAD+ is a coenzyme found in every living cell. It participates in over 500 enzymatic reactions and serves two fundamental roles:
1. **Redox metabolism**: NAD+ shuttles electrons during cellular energy production, particularly in the mitochondria during oxidative phosphorylation. Without adequate NAD+, your cells cannot efficiently convert nutrients into ATP — the energy currency that powers virtually every biological function.
2. **Substrate for signaling enzymes**: NAD+ is consumed (not just borrowed) by several families of enzymes that regulate DNA repair, gene expression, inflammation, and cellular stress responses. Every time these enzymes do their job, they break down an NAD+ molecule in the process.
This second role is critical for understanding the NAD+-longevity connection. The enzymes that consume NAD+ — particularly sirtuins, PARPs, and CD38 — are deeply involved in the biology of aging. As NAD+ levels fall, these systems compete for a shrinking pool of a molecule they all need to function.
The Age-Related Decline
Multiple studies have documented that NAD+ levels decrease significantly with age. Research published in *Cell Metabolism* and other journals has measured this decline across tissues including muscle, liver, brain, and blood. By middle age, NAD+ levels may be substantially lower than they were in youth.
The question that has driven a decade of research: **Is this decline a bystander of aging, or a driver of it?**
The emerging consensus, supported by extensive preclinical data and growing human research, suggests it is both — a consequence of aging processes that also accelerates them, creating a feedback loop.
---
The Three Pillars: Sirtuins, PARPs, and Mitochondrial Function
To understand how NAD+ connects to longevity, you need to understand the three major NAD+-dependent systems that intersect with aging hallmarks.
Sirtuins: The Metabolic Sensors
Sirtuins (SIRT1–SIRT7) are a family of NAD+-dependent deacetylase enzymes. They remove acetyl groups from proteins, which changes how those proteins behave. Sirtuins regulate:
- **DNA repair and genomic stability** — SIRT1 and SIRT6 help coordinate the cellular response to DNA damage - **Mitochondrial biogenesis** — SIRT1 and SIRT3 activate pathways (including PGC-1α) that promote the creation of new mitochondria - **Inflammation** — SIRT1 modulates NF-κB signaling, a master regulator of inflammatory gene expression - **Epigenetic maintenance** — Sirtuins help maintain the epigenetic marks that keep genes properly regulated as cells divide
In animal models, overexpression of certain sirtuins has extended lifespan in yeast, worms, flies, and mice. Conversely, sirtuin dysfunction accelerates features of aging. Because sirtuins require NAD+ to function, declining NAD+ levels directly impair sirtuin activity.
**What the human data shows**: Human studies have confirmed that sirtuin activity correlates with NAD+ availability in blood and tissue samples. However, the dramatic lifespan extension seen in animal models has not been replicated in human trials — nor would we expect it to be, given the complexity and length of human aging. What researchers are tracking instead are biomarkers of sirtuin-regulated processes: inflammatory markers, mitochondrial function metrics, and epigenetic clocks.
PARPs: The DNA Repair Crew
Poly(ADP-ribose) polymerases — particularly PARP1 — are NAD+-consuming enzymes that play a central role in detecting and repairing DNA damage. When a DNA strand breaks, PARP1 rapidly binds to the damage site and uses NAD+ to build poly(ADP-ribose) chains that recruit repair machinery.
The problem: DNA damage accumulates with age. As PARP activity increases to handle this growing repair burden, it consumes more NAD+, depleting the pool available for sirtuins and other processes. This creates a competition dynamic — more DNA damage means more PARP activity, which means less NAD+ for everything else.
Animal studies have shown that PARP inhibition or NAD+ supplementation can partially restore the balance, improving markers of cellular health in aged mice. In humans, PARP activity and NAD+ consumption have been measured in blood cells, confirming the competitive dynamic exists, but long-term intervention data remains limited.
Mitochondrial Function: The Energy Crisis
Mitochondrial dysfunction is one of the most well-established hallmarks of aging. As mitochondria deteriorate, cells produce less energy, generate more reactive oxygen species (ROS), and become less resilient to stress.
NAD+ connects to mitochondrial health through multiple pathways:
- **Direct role in the electron transport chain**: NAD+ (as NADH) is essential for complexes I through the mitochondrial respiratory chain - **SIRT3 activation**: This mitochondria-localized sirtuin, dependent on NAD+, regulates enzymes involved in fatty acid oxidation, the TCA cycle, and antioxidant defense - **Mitophagy regulation**: NAD+-dependent signaling helps cells identify and recycle damaged mitochondria
In aged mice, NAD+ repletion has been shown to restore mitochondrial function, improve exercise capacity, and reverse age-related muscle deterioration. These are among the most compelling preclinical findings in the NAD+ field.
**The human translation**: Several small human trials have measured improvements in mitochondrial biomarkers following NAD+ precursor supplementation. A 2020 study in *Nature Communications* found that NMN (an NAD+ precursor) improved muscle insulin sensitivity and mitochondrial function markers in prediabetic women. However, the magnitude of effects in humans has generally been more modest than in rodent models, and larger, longer-duration trials are still underway.
---
NAD+ Precursors vs. Direct NAD+: Understanding the Delivery Question
Most oral supplements use NAD+ precursors — primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — because NAD+ itself is a large molecule with limited oral bioavailability. These precursors enter cells and are converted to NAD+ through salvage pathway enzymes.
The precursor approach has generated the majority of published human trial data. Key findings include:
- **NR supplementation** has been shown to raise blood NAD+ levels in multiple human trials, though the degree of tissue-level NAD+ repletion varies - **NMN supplementation** has demonstrated NAD+ elevation in blood and has shown effects on specific metabolic parameters in small trials - **Direct NAD+ administration** (via intravenous or subcutaneous routes) bypasses the oral bioavailability question entirely, delivering NAD+ directly into the bloodstream
Clinician-supervised NAD+ therapy, as offered through telehealth platforms, typically involves direct NAD+ formulations rather than oral precursors. The rationale is straightforward: direct delivery avoids the conversion bottlenecks and variable absorption that can limit oral precursor efficacy.
It is important to note that compounded NAD+ formulations are not FDA-approved drugs. They are prepared by licensed compounding pharmacies under clinician prescription and are designed to help with cellular NAD+ repletion as part of a supervised wellness protocol.
---
What Human Trials Actually Show (and Don't Show)
Honesty about the evidence base is essential. Here is where the science stands as of current published literature:
What Human Data Supports
- **NAD+ precursors reliably raise blood NAD+ levels** in healthy adults and older populations across multiple randomized controlled trials - **Safety profiles have been favorable** in trials lasting up to 12 weeks, with no serious adverse events reported at standard doses - **Specific metabolic parameters** — including insulin sensitivity, blood lipid markers, and inflammatory biomarkers — have shown improvements in some (but not all) trials - **Mitochondrial function markers** have improved in targeted populations (e.g., the prediabetic women study mentioned above) - **Exercise performance and recovery metrics** have shown modest improvements in some trials, particularly in older adults
Where We're Still Extrapolating from Animal Models
- **Lifespan extension**: No human trial has demonstrated (or could yet demonstrate) that NAD+ repletion extends human lifespan. The mouse data is compelling, but direct translation is unproven. - **Neurodegeneration**: Animal models show NAD+ repletion may support neuronal health, but human neurodegenerative disease trials are in early stages - **Epigenetic age reversal**: Some animal studies suggest NAD+ repletion can slow or partially reverse epigenetic aging clocks. Human epigenetic clock data from NAD+ interventions is preliminary - **Tissue-specific repletion**: Whether raising blood NAD+ levels translates to meaningful increases in brain, heart, or muscle NAD+ in humans remains an active research question
The Honest Bottom Line
The mechanistic rationale for NAD+ and longevity is strong and well-supported by decades of biochemistry and extensive animal research. Human data confirms that NAD+ levels can be raised and that doing so may support metabolic, mitochondrial, and cellular repair functions. However, the dramatic aging-reversal effects seen in mice have not been fully replicated in human trials — and anyone claiming otherwise is getting ahead of the evidence.
What the data does support is that NAD+ repletion may support the body's natural repair and energy production systems that decline with age. That is a meaningful and scientifically grounded rationale for supervised NAD+ therapy, even as we await larger and longer human trials.
---
Why Clinician Supervision Matters
NAD+ therapy is not a simple supplement-and-forget intervention. Dosing, delivery method, individual health status, and monitoring all matter. Factors that influence an appropriate NAD+ protocol include:
- **Baseline NAD+ status and metabolic health** - **Concurrent medications** (particularly those affecting NAD+-consuming enzymes) - **Delivery route selection** (oral precursors vs. direct NAD+ formulations) - **Monitoring of response** through biomarkers and clinical assessment
A clinician-supervised approach ensures that NAD+ therapy is tailored to individual needs and adjusted based on response — not a one-size-fits-all protocol.
---
Exploring NAD+ Therapy Through PepScribe
PepScribe is a telehealth platform that connects you with licensed clinicians who can evaluate whether NAD+ therapy is appropriate for your individual health goals. PepScribe does not manufacture, compound, or dispense medications — prescriptions are filled by licensed compounding pharmacies when clinically appropriate.
If you're researching NAD+ and longevity, the next step is a clinical conversation — not a shopping cart.
**[See all available options](See all available options)** to explore what NAD+ and other formulations may be available through PepScribe's clinician network.
Want to stay informed as new NAD+ research is published? **Get longevity updates** delivered to your inbox with our latest evidence reviews and protocol insights.
---
Disclosure
This content is for informational and educational purposes only. It is not medical advice and does not substitute for consultation with a qualified healthcare provider. Compounded NAD+ formulations are not FDA-approved drugs. Individual results vary. All therapy decisions should be made in consultation with a licensed clinician who can evaluate your specific health status and goals. PepScribe is a telehealth platform and does not manufacture, compound, or dispense medications.
---
*Last reviewed by the PepScribe editorial team. Content reflects published research available at the time of writing and will be updated as new data emerges.*